Viridian Therapeutics, Inc./DE (VRDN) Current Ratio
- Current ratio · latest quarter: Value 16.95×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 16.95× | Current assets / current liabilities. $1.08B ÷ $63.79M ≈ 16.95× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.08B USD | Assets, Current |
| Current obligations | 63.79M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 816.54M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | 8.65M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.08B | $63.79M | (m) | $816.54M | (m) | (m) | $8.65M | (m) | 16.95× |
| 2026-03-31 | $784.74M | $51.80M | (m) | $585.84M | (m) | (m) | $13.31M | (m) | 15.15× |
| 2025-12-31 | $894.23M | $70.70M | (m) | $662.27M | (m) | (m) | $8.68M | (m) | 12.65× |
| 2025-09-30 | $571.91M | $50.70M | (m) | $321.25M | (m) | (m) | $10.06M | (m) | 11.28× |
| 2025-06-30 | $578.75M | $52.59M | (m) | $446.03M | (m) | (m) | $8.52M | $8.44M | 11.01× |
| 2025-03-31 | $657.24M | $33.73M | (m) | $520.42M | (m) | (m) | $3.89M | (m) | 19.49× |
| 2024-12-31 | $738.46M | $47.87M | (m) | $617.99M | (m) | (m) | $2.14M | (m) | 15.43× |
| 2024-09-30 | $767.36M | $41.36M | (m) | $552.92M | (m) | (m) | $6.34M | (m) | 18.55× |
| 2024-06-30 | $581.66M | $36.76M | (m) | $463.70M | (m) | (m) | $3.14M | $2.96M | 15.82× |
| 2024-03-31 | $626.82M | $26.13M | (m) | $521.55M | (m) | (m) | $2.68M | (m) | 23.99× |
| 2023-12-31 | $486.48M | $26.64M | (m) | $374.54M | (m) | (m) | $2.24M | (m) | 18.26× |
| 2023-09-30 | $323.84M | $23.25M | (m) | $201.41M | (m) | (m) | $3.73M | (m) | 13.93× |
| 2023-06-30 | $346.33M | $28.66M | (m) | $247.21M | (m) | (m) | $4.13M | (m) | 12.09× |
| 2023-03-31 | $382.60M | $29.59M | (m) | $285.34M | (m) | (m) | $7.87M | (m) | 12.93× |
| 2022-12-31 | $431.17M | $33.35M | (m) | $268.97M | (m) | (m) | $14.23M | (m) | 12.93× |
| 2022-09-30 | $437.36M | $25.21M | (m) | $87.11M | (m) | (m) | $12.15M | (m) | 17.35× |
| 2022-06-30 | $166.15M | $21.39M | (m) | $129.91M | (m) | (m) | $4.06M | (m) | 7.77× |
| 2022-03-31 | $179.39M | $14.39M | (m) | (m) | (m) | (m) | $2.54M | (m) | 12.47× |
| 2021-12-31 | $200.16M | $13.64M | (m) | $154.67M | (m) | (m) | $2.33M | (m) | 14.68× |
| 2021-09-30 | $217.94M | $14.34M | (m) | (m) | (m) | (m) | $3.73M | (m) | 15.20× |
| 2021-06-30 | $115.46M | $16.83M | (m) | (m) | (m) | (m) | $2.39M | (m) | 6.86× |
| 2021-03-31 | $121.53M | $16.44M | (m) | (m) | (m) | (m) | $3.38M | (m) | 7.39× |
| 2020-12-31 | $129.61M | $10.67M | (m) | (m) | (m) | (m) | $670.00K | (m) | 12.14× |
| 2020-09-30 | $31.97M | $7.56M | (m) | (m) | $57.00K | (m) | $232.00K | (m) | 4.23× |
| 2020-06-30 | $32.52M | $6.72M | (m) | (m) | $248.00K | (m) | $286.00K | (m) | 4.84× |
| 2020-03-31 | $38.34M | $8.66M | (m) | (m) | $4.00K | (m) | $1.63M | (m) | 4.43× |
| 2019-12-31 | $29.74M | $10.18M | (m) | (m) | (m) | (m) | $1.10M | (m) | 2.92× |
| 2019-09-30 | $38.22M | $10.38M | $24.86M | (m) | $979.00K | (m) | $1.56M | (m) | 3.68× |
| 2019-06-30 | $48.08M | $9.15M | $24.01M | (m) | $325.00K | (m) | $1.23M | (m) | 5.26× |
| 2019-03-31 | $54.21M | $6.86M | $18.20M | (m) | $6.00K | (m) | $517.00K | (m) | 7.90× |
| 2018-12-31 | $65.37M | $6.73M | (m) | (m) | $24.00K | (m) | $571.00K | (m) | 9.71× |
| 2018-09-30 | $75.75M | $6.83M | $31.70M | (m) | $1.38M | (m) | $1.21M | (m) | 11.09× |
| 2018-06-30 | $81.22M | $4.28M | $43.40M | (m) | $1.20M | (m) | $461.00K | (m) | 18.96× |
| 2018-03-31 | $86.35M | $4.14M | $78.10M | (m) | $4.81M | (m) | $760.00K | (m) | 20.87× |
| 2017-12-31 | $51.87M | $3.90M | $47.44M | (m) | $1.46M | (m) | $906.00K | (m) | 13.31× |
| 2017-09-30 | $46.42M | $6.53M | $42.80M | (m) | $635.00K | (m) | $409.00K | (m) | 7.10× |
| 2017-06-30 | $49.35M | $6.63M | $46.34M | (m) | $539.00K | (m) | $632.00K | (m) | 7.44× |
| 2017-03-31 | $56.94M | $7.28M | $54.27M | (m) | $277.00K | (m) | $1.13M | (m) | 7.82× |
| 2016-12-31 | $23.88M | $6.88M | $22.10M | (m) | $20.00K | (m) | $1.01M | (m) | 3.47× |
| 2016-09-30 | $6.51M | $2.85M | $5.35M | (m) | $733.00K | $62.00K | $51.00K | (m) | 2.28× |
| 2016-06-30 | $7.97M | $2.60M | $6.50M | (m) | $658.00K | $213.00K | $94.00K | (m) | 3.07× |
| 2016-03-31 | $9.67M | $2.44M | $8.56M | (m) | $490.00K | $269.00K | $102.00K | (m) | 3.96× |
| 2015-12-31 | $11.73M | $2.47M | $10.83M | (m) | $394.00K | $187.00K | $242.00K | (m) | 4.75× |
| 2015-09-30 | $13.61M | $2.11M | $12.12M | (m) | $547.00K | $364.00K | $195.00K | (m) | 6.44× |
| 2015-06-30 | $11.86M | $2.08M | (m) | (m) | $581.00K | $536.00K | $332.00K | (m) | 5.72× |
| 2015-03-31 | $14.49M | $2.50M | (m) | (m) | $598.00K | $330.00K | $384.00K | (m) | 5.81× |
| 2014-12-31 | $6.79M | $1.99M | $5.12M | (m) | $1.09M | $179.00K | $255.00K | (m) | 3.41× |
| 2014-09-30 | $8.66M | $2.00M | $6.39M | (m) | $1.55M | $232.06K | $238.52K | (m) | 4.34× |
| 2014-06-30 | $9.77M | $2.14M | $7.70M | (m) | $1.36M | $193.14K | $167.74K | (m) | 4.57× |
| 2013-12-31 | $2.06M | $27.30M | (m) | (m) | $994.00K | $357.00K | $100.00K | (m) | 0.08× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |